CoChat

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease

Subramaniam, K., Fallon, K., Ruut, T., Lane, D., McKay, R., Shadbolt, B., Ang, S., Cook, M., Platten, J., Pavli, P., Taupin, D. · 2015 · Alimentary Pharmacology & Therapeutics
Cited by 145

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Summary: Background: Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF‐κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim: As TNF is a potent activator of NF‐κB, and anti‐TNF agent infliximab (IFX) prevents NF‐κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods: We performed a prospective, repeated‐measures cohort study in adult Crohn's disease patients with an acute disease flare. Patients were instructed not to vary diet or activity. Concomitant medications were kept stable. At week 1 (pre‐treatment), week 16 (post‐IFX induction) and week 25 (post‐first IFX maintenance dose), we assessed (i) MRI volume of quadriceps femoris at anatomical mid‐thigh; (ii) maximal concentric quadriceps contractions strength at three specific speeds of contraction; (iii) physical activity by validated instrument (IPAQ); (iv) Three‐day food record of intake and composition (food‐weighing method); (v) Serum levels of IL 6. Results: Nineteen patients (58% female; mean age 33.2 ± 10.7 years) were recruited. IFX increased muscle volume in both legs from baseline (right, 1505 cm 3) to week 25 (right, 1569 cm 3; P = 0.010). IFX also increased muscle strength in both legs from baseline (right 30°/s, 184.8 Nm) to week 25 (right 30°/s, 213.6 Nm; P = 0.002). Muscle volume gain correlated with male gender (P = 0.003). Significant gains in muscle volume and strength were unrelated to prednisolone use. Serum IL 6 levels decreased by week 25 (P = 0.037). Conclusion: The anti‐TNF agent infliximab reverses inflammatory sarcopenia in patients with Crohn's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.13058

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Subramaniam, K., Fallon, K., Ruut, T., Lane, D., McKay, R., Shadbolt, B., Ang, S., Cook, M., Platten, J., Pavli, P., & Taupin, D.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2015-01-08
Volume
41
Issue
5
Pages
419-428
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2048549581
Cited by
145
References
12
FWCI
7.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.